Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
The study reports results for using afatinib as first-line therapy in patients with EGFR mutation-positive, advanced non-small cell lung can…
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response [Phase 2]
This clinical trial update outlines a two-cohort Phase 2 exploratory study evaluating benmelstobart alone or in combination with anlotinib b…
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: Personalized DC Vaccine for Postoperative Cancer [Phase 1]
A Phase 1 clinical trial evaluating a personalized dendritic cell vaccine for postoperative gastric cancer and hepatocellular carcinoma is c…
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer [NA]
A Ballad Health-sponsored clinical trial is evaluating longitudinal plasma PD-L1 testing in non-small cell lung cancer patients treated with…
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC [Phase 2]
A Phase 2 trial evaluated combining osimertinib with aspirin to overcome resistance to first-generation EGFR-TKIs in non-small cell lung can…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: Vapor Ablation for Localized Cancer Lesions [NA]
Clinical trial update indicating vapor ablation therapy is not yet recruiting for localized cancer lesions, including non-small cell lung ca…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC [Phase 2]
A Phase 2 clinical trial update from Peking University investigates immunotherapy with hypofractionated concurrent chemoradiotherapy followe…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial [NA]
A clinical trial update describing a study of Xingbai Ji Formula combined with chemotherapy and Sintilimab for metastatic multi-target mutat…
-
CLINICAL_TRIALS trial_result · 2025-02-26Clinical Trial Update: A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer [Phase 3]
A Phase 3 clinical trial is planned to compare HLX17 with pembrolizumab (Keytruda) as first-line treatment in advanced non-squamous non-smal…
-
CLINICAL_TRIALS trial_result · 2025-02-26Clinical Trial Update: A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer [Phase 1, Phase 2]
A Phase 1/2 study evaluating bemcentinib in combination with erlotinib in non-small cell lung cancer has completed and posted results.
-
CLINICAL_TRIALS research · 2025-02-26Clinical Trial Update: DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC
The DREAM Study is a clinical trial evaluating DNA/RNA next-generation sequencing co-testing for driver-negative, treatment-resistant non-sm…
-
CLINICAL_TRIALS trial_result · 2025-02-25Clinical Trial Update: Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC [Phase 2]
Phase 2 clinical trial update evaluating chemotherapy combined with immune checkpoint inhibitors in ALK-rearranged non-small cell lung cance…
-
CLINICAL_TRIALS research · 2025-02-25Clinical Trial Update: Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
This ClinicalTrials.gov entry describes a longitudinal cohort study of lung cancer using tissue and peripheral blood metabolomics, currently…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors [Phase 1, Phase 2]
Clinical trial update on a Phase 1/2 study evaluating AL3818 in combination with nivolumab for solid tumors; the trial is currently not recr…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies [Phase 1]
A Phase 1 study of TGRX-1942 for advanced solid tumors and/or relapsed/refractory hematologic malignancies is currently recruiting in China.
-
CLINICAL_TRIALS trial_result · 2025-02-21Clinical Trial Update: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) [Phase 3]
Phase 3 trial evaluating pemetrexed with platinum-based chemotherapy and pembrolizumab, with or without lenvatinib, as first-line therapy fo…
-
CLINICAL_TRIALS research · 2025-02-21Clinical Trial Update: TGRX-326 Pharmacokinetic Mass Balance [Phase 1]
A Phase 1 pharmacokinetic mass balance study of TGRX-326 in non-small cell lung cancer has completed.
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors [Phase 1, Phase 2]
ImmunityBio's QUILT-3.044 trial evaluating the NANT NSCLC vaccine in patients who progressed after PD-1/PD-L1 inhibitors has been withdrawn.
-
CLINICAL_TRIALS research · 2025-02-21Clinical Trial Update: Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) [Phase 2]
Phase 2 trial (PACE-LUNG) evaluating additional chemotherapy in EGFR mutation-positive non-small cell lung cancer patients who have persiste…
-
CLINICAL_TRIALS research · 2025-02-21Clinical Trial Update: Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
This clinical trial update describes a study to assess the association between RVT and prognosis after neoadjuvant targeted therapy in EGFR-…
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating NANT immunotherapy for resectable non-small cell lung cancer has been withdrawn from the study.
-
CLINICAL_TRIALS research · 2025-02-20Clinical Trial Update: Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists [NA]
A clinical trial update aimed at identifying predictive factors of response to PD-1/PD-L1 inhibitors across multiple cancers, including mela…
-
CLINICAL_TRIALS research · 2025-02-20Clinical Trial Update: Injection of 99mTc-nanocolloid and ICG to Identify, Retrieve and Qualify TDLN in Early-stage NSCLC [NA]
A clinical trial update describing the use of Technetium-99m nanocolloid and Indocyanine Green to identify sentinel lymph nodes in early-sta…
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial of Quaratusugene ozeplasmid (Reqorsa) in combination with pembrolizumab for previously treated non-small cell lun…
-
CLINICAL_TRIALS research · 2025-02-20Clinical Trial Update: Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC [Phase 2]
Phase 2 trial update comparing neoadjuvant chemotherapy plus a bispecific antibody versus a monoclonal antibody in locally advanced non-smal…